SCHEMBL3843952

SCHEMBL3843952

O=C(O)NCCCCI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025533 0.97 KDM4E (0.44)
SCHEMBL21634363 0.97 KDM4E (0.44)
SCHEMBL7533949 0.97 KDM4E (0.44)
SCHEMBL5533897 0.97 KDM4E (0.44)
SCHEMBL3879064 0.92
SCHEMBL3174690 0.86 KDM4E (0.50)
SCHEMBL2029681 0.83 KDM4E (0.55)
SCHEMBL5569558 0.83 KDM4E (0.55)
SCHEMBL20836564 0.83 KDM4E (0.55)
SCHEMBL30541972 0.83 KDM4E (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050036976-A1 Topical skin care composition RUBIN JOEL (US) 2005-02-17 US claimed
WO-2024097948-A1 DEGRADERS OF MDM2 AND USES THEREOF ROIVANT DISCOVERY, INC. (US) 2024-05-10 WO disclosed
US-20240110015-A1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX B.V. (NL) 2024-04-04 US disclosed
US-11884781-B2 Supramolecular biomedical polymers SUPRAPOLIX B.V. (NL) 2024-01-30 US disclosed
EP-3713990-B1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX BV (NL) 2023-08-02 EP disclosed
CN-108546643-B Process for large scale enzymatic synthesis of oligosaccharides 台湾地区“中央研究院” 2022-02-25 CN disclosed
CN-108611384-B Process for large scale enzymatic synthesis of oligosaccharides 台湾地区“中央研究院” 2022-02-25 CN disclosed
CN-112955008-A Method for preventing and treating wheat diseases, wheat seeds and method for suppressing lodging loss of wheat 组合化学工业株式会社 2021-06-11 CN disclosed
EP-3713990-A1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SupraPolix B.V. (NL) 2020-09-30 EP disclosed
US-20200277448-A1 SUPRAMOLECULAR BIOMEDICAL POLYMERS SUPRAPOLIX B.V. (NL) 2020-09-03 US disclosed
EP-1653961-A4 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORP (US) 2009-04-01 EP disclosed
US-20080255143-A1 Inhibitors of Akt Activity SMITHKLINE BEECHAM CORPORATION (PA) 2008-10-16 US disclosed
EP-1653961-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
US-6949577-B2 Pharmaceuticals PFIZER, INC. (US) 2005-09-27 US disclosed
US-20050036976-A1 Topical skin care composition RUBIN JOEL (US) 2005-02-17 US disclosed
WO-2005011700-A1 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-02-10 WO disclosed
US-20030236420-A1 Pharmaceuticals ALLERTON CHARLOTTE MOIRA NORFO (GB) 2003-12-25 US disclosed
EP-1311488-A1 SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS Pfizer Limited (GB) 2003-05-21 EP disclosed
US-20020147229-A1 Pharmaceuticals PFIZER INC. 2002-10-10 US disclosed
WO-2002014285-A1 SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS PFIZER LIMITED (GB) 2002-02-21 WO disclosed